For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Including Senior Research Executives from Boehringer Ingelheim and the Garvan Institute
Pharmaxis hosted an investor research briefing on 20th November 2018 featuring presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event provided an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program.
Pharmaxis CEO Gary Phillips, Board member Dr Kathleen Metters and Head of Drug Discovery Wolfgang Jarolimek provided commercial and scientific perspectives.
Video recordings of all the presentations can be viewed from this link.
Pharmaxis Anti-Fibrotic LOX Inhibitor Program for Pancreatic Cancer Ready to Commence Phase 1 Clinical Trials
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced it has completed the preclinical package on its anti-fibrotic Lysyl Oxidase (LOX) program focused on pancreatic cancer and will this week file an ethics submission to enable progress into a Phase 1 clinical trial in healthy volunteers. The trial is planned to commence in the first quarter of 2019. It is the third program from the Company’s amine oxidase chemistry platform to reach the important stage of entering human clinical trials.
Pharmaxis is the first company to progress a small molecule LOX inhibitor into clinical development. The compound is an oral once-a-day drug that inhibits all lysyl oxidase family members (LOX, LOXL1, 2, 3 & 4). It successfully cleared pre-clinical safety and toxicity studies in the third quarter of 2018 and has shown significant reductions in fibrosis in in-vivo models of kidney fibrosis, lung fibrosis, myelofibrosis and pancreatic cancer. Whereas the Pharmaxis selective LOXL2 inhibitors that are currently completing phase 1 studies are suited to chronic fibrotic conditions such as IPF and NASH, this all-encompassing LOX inhibitor is well positioned for the treatment of severe fibrosis as well as cancer with prominent stroma (connective tissue) or fibrotic metastatic niches. Pharmaxis plans to initially develop the compound for pancreatic cancer.
Pharmaxis is collaborating with Garvan Institute of Medical Research to investigate the therapeutic potential of LOX inhibition in pancreatic cancer.Read full media release - pdf
Pharmaceutical company Pharmaxis (ASX: PXS) today announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Repeating the positive results seen in the Phase 1 trial of the first inhibitor compound announced on 11 October 2018, the excellent drug like properties demonstrated in earlier pre-clinical testing were confirmed. There were no adverse safety findings in either the first or second stages of the study and the pharmacokinetic profile showed the expected dose related increases in exposure.
Significant target engagement of the LOXL2 enzyme by both compounds has now been demonstrated in blood serum for a full 24 hours from a single dose over a 14-day period, with the second compound achieving more than 85% inhibition over 24 hours from a 100mg daily dose, achieving the target for this program.Read full media release - pdf